How the diabetic eye loses vision

The objective is to review the most common causes of vision loss in patients with diabetes with the goal of better managing patients with diabetic eye disease. In this review, the causes of vision loss, and the clinical evaluation and management of diabetic retinopathy (DR) and diabetic macular edema (DME) are outlined. Patients with diabetes mellitus have an increased risk of vision loss and blindness. In patients with diabetes, the primary mechanism responsible for vision loss is centrally involved DME or clinically significant macular edema (CSME), defined as vascular leakage resulting in fluid accumulation that affects the center of the macula. DR and DME are thought to result from the effects of excessive blood glucose on the vessels that produces microvascular damage. The progression of DR can be slowed by intensive glycemic and blood pressure control. Severe visual loss from proliferative DR and moderate visual loss from DME can be reduced by laser photocoagulation. DR and DME are diagnosed on dilated retinal examination and confirmed with diagnostic testing. Many experts and associations recommend that patients with diabetes have an yearly, thorough, dilated eye exam. This manuscript describes the case history of a patient with diabetes and vision loss.

[1]  M. Engelgau,et al.  Diabetes trends in the U.S.: 1990-1998. , 2000, Diabetes care.

[2]  B. Zinman,et al.  Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. , 2003, Diabetes care.

[3]  Frank A Sloan,et al.  Longitudinal rates of annual eye examinations of persons with diabetes and chronic eye diseases. , 2003, Ophthalmology.

[4]  L. Aiello,et al.  Retinopathy in diabetes. , 2004, Diabetes care.

[5]  M. C. Leske,et al.  The prevalence of diabetic retinopathy among adults in the United States. , 2004, Archives of ophthalmology.

[6]  G. M. Zoega,et al.  Screening compliance and visual outcome in diabetes. , 2005, Acta ophthalmologica Scandinavica.

[7]  S. Azen,et al.  The impact of visual impairment on self-reported visual functioning in Latinos: The Los Angeles Latino Eye Study. , 2004, Ophthalmology.

[8]  A. Sommer,et al.  Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. , 1991, JAMA.

[9]  Paul G Shekelle,et al.  Preventing visual loss from chronic eye disease in primary care: scientific review. , 2004, JAMA.

[10]  R. Klein,et al.  Ten-year incidence of visual loss in a diabetic population. , 1994, Ophthalmology.

[11]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[12]  L. Groop,et al.  Progression to proliferative retinopathy and macular oedema requiring treatment. Assessment of the alternative classification of the Wisconsin Study. , 1999, Acta ophthalmologica Scandinavica.

[13]  D L DeMets,et al.  The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. , 1984, Archives of ophthalmology.

[14]  R. Klein,et al.  The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. , 1998, Ophthalmology.

[15]  Gary C. Brown,et al.  Quality of life associated with visual loss: a time tradeoff utility analysis comparison with medical health states. , 2003, Ophthalmology.

[16]  H. Quigley,et al.  Models of open-angle glaucoma prevalence and incidence in the United States. , 1997, Investigative ophthalmology & visual science.

[17]  N. Congdon,et al.  Important causes of visual impairment in the world today. , 2003, JAMA.

[18]  D. Cabrol,et al.  [Clinical practice recommendations. Risk of premature birth with intact membranes. Conclusions (2002)]. , 2003, Gynecologie, obstetrique & fertilite.

[19]  S. Feld,et al.  The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: The AACE System of Intensive Diabetes Self-Management - 2002 Update , 2002 .

[20]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[21]  R. Klein,et al.  Causes and prevalence of visual impairment among adults in the United States. , 2004, Archives of ophthalmology.

[22]  Matthew D. Davis,et al.  Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. , 2003, Ophthalmology.

[23]  Wei Liu,et al.  The impact of diabetic retinopathy on health-related quality of life. , 2005, Current opinion in ophthalmology.

[24]  D L DeMets,et al.  The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. , 1984, Ophthalmology.

[25]  T. Ciulla,et al.  Current and future pharmacological intervention for diabetic retinopathy , 2005, Expert opinion on emerging drugs.

[26]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[27]  D. DeMets,et al.  The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. , 1984, Archives of ophthalmology.